دورية أكاديمية
Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination.
| العنوان: | Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. |
|---|---|
| المؤلفون: | Matsui Y; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA., Li L; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Prahl M; Department of Pediatrics.; Division of Pediatric Infectious Diseases and Global Health., Cassidy AG; Division of Maternal-Fetal Medicine and., Ozarslan N; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Golan Y; Department of Bioengineering and Therapeutic Sciences., Gonzalez VJ; Division of Maternal-Fetal Medicine and., Lin CY; Division of Maternal-Fetal Medicine and., Jigmeddagva U; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Chidboy MA; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Montano M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA., Taha TY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Khalid MM; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Sreekumar B; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Hayashi JM; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Chen PY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Kumar GR; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Warrier L; Department of Family Health Care Nursing, and., Wu AH; Department of Laboratory Medicine, UCSF, San Francisco, California, USA., Song D; Department of Pediatrics, Division of Neonatology, Santa Clara Valley Medical Center, San Jose, California, USA., Jegatheesan P; Department of Pediatrics, Division of Neonatology, Santa Clara Valley Medical Center, San Jose, California, USA., Rai DS; Stanford-O'Connor Family Medicine Residency Program, Division of Family Medicine, Stanford University, Palo Alto, California, USA., Govindaswami B; Department of Pediatrics, Division of Neonatology, and., Needens J; Department of Obstetrics and Gynecology, Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia, USA., Rincon M; Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon, USA., Myatt L; Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon, USA., Asiodu IV; Department of Family Health Care Nursing, and., Flaherman VJ; Department of Pediatrics., Afshar Y; Department of Obstetrics and Gynecology, UCLA, Los Angeles, California, USA., Jacoby VL; Department of Obstetrics, Gynecology & Reproductive Sciences., Murtha AP; Division of Maternal-Fetal Medicine and., Robinson JF; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Ott M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA.; Department of Medicine, and., Greene WC; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA.; Department of Medicine, and.; Department of Microbiology and Immunology, UCSF, San Francisco, California, USA., Gaw SL; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA. |
| المصدر: | JCI insight [JCI Insight] 2022 Jun 22; Vol. 7 (12). Date of Electronic Publication: 2022 Jun 22. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , SARS-CoV-2*, Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Female ; Gestational Age ; Humans ; Mothers ; Neutralization Tests ; Vaccination |
| مستخلص: | Pregnancy confers unique immune responses to infection and vaccination across gestation. To date, there are limited data comparing vaccine- and infection-induced neutralizing Abs (nAbs) against COVID-19 variants in mothers during pregnancy. We analyzed paired maternal and cord plasma samples from 60 pregnant individuals. Thirty women vaccinated with mRNA vaccines (from December 2020 through August 2021) were matched with 30 naturally infected women (from March 2020 through January 2021) by gestational age of exposure. Neutralization activity against the 5 SARS-CoV-2 spike sequences was measured by a SARS-CoV-2-pseudotyped spike virion assay. Effective nAbs against SARS-CoV-2 were present in maternal and cord plasma after both infection and vaccination. Compared with WT spike protein, these nAbs were less effective against the Delta and Mu spike variants. Vaccination during the third trimester induced higher cord-nAb levels at delivery than did infection during the third trimester. In contrast, vaccine-induced nAb levels were lower at the time of delivery compared with infection during the first trimester. The transfer ratio (cord nAb level divided by maternal nAb level) was greatest in mothers vaccinated in the second trimester. SARS-CoV-2 vaccination or infection in pregnancy elicits effective nAbs with differing neutralization kinetics that are influenced by gestational time of exposure. |
| References: | Obstet Gynecol. 2021 Aug 1;138(2):189-197. (PMID: 33910220) JAMA Netw Open. 2021 Aug 2;4(8):e2120456. (PMID: 34379123) J Med Virol. 2021 Sep;93(9):5638-5643. (PMID: 33951211) Am J Obstet Gynecol MFM. 2021 Nov;3(6):100467. (PMID: 34425297) Obstet Gynecol. 2021 Aug 1;138(2):278-280. (PMID: 33910219) Nature. 2021 Aug;596(7871):276-280. (PMID: 34237773) Am J Obstet Gynecol MFM. 2022 Jan;4(1):100492. (PMID: 34547533) Nat Commun. 2021 Jul 7;12(1):4196. (PMID: 34234131) MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. (PMID: 35176002) Clin Dev Immunol. 2012;2012:985646. (PMID: 22235228) Front Cardiovasc Med. 2021 Jan 15;7:618651. (PMID: 33521067) Front Immunol. 2019 Jul 10;10:1540. (PMID: 31354709) Sci Transl Med. 2021 Oct 27;13(617):eabi7428. (PMID: 34664987) JAMA Netw Open. 2020 Dec 1;3(12):e2030455. (PMID: 33351086) J Clin Invest. 2021 Oct 1;131(19):. (PMID: 34596052) J Med Virol. 2021 Mar;93(3):1361-1369. (PMID: 33090535) MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):719-724. (PMID: 33988185) Adv Nutr. 2016 Jan 15;7(1):66-75. (PMID: 26773015) Vaccines (Basel). 2021 Jun 19;9(6):. (PMID: 34205434) JAMA. 2021 Mar 16;325(11):1037-1038. (PMID: 33595644) Clin Infect Dis. 2021 Jan 27;72(2):301-308. (PMID: 33501951) Virol J. 2021 Apr 28;18(1):87. (PMID: 33910569) Rev Med Virol. 2022 Mar;32(2):e2277. (PMID: 34286893) Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17. (PMID: 33775692) Int J Infect Dis. 2020 Dec;101:380-381. (PMID: 33045426) BMJ Open. 2021 Jul 7;11(7):e053036. (PMID: 34234001) Rev Reprod. 1999 May;4(2):81-9. (PMID: 10357095) JAMA. 2021 Jun 15;325(23):2370-2380. (PMID: 33983379) N Engl J Med. 2021 Dec 16;385(25):2397-2399. (PMID: 34731554) Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. (PMID: 33592168) Cell. 2021 Feb 4;184(3):628-642.e10. (PMID: 33476549) Nat Immunol. 2021 Dec;22(12):1490-1502. (PMID: 34616036) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448) JAMA. 2021 Aug 24;326(8):728-735. (PMID: 34251417) Am J Reprod Immunol. 1996 Nov;36(5):248-55. (PMID: 8955500) J Med Virol. 2021 Dec;93(12):6468-6470. (PMID: 34329486) J Chem Inf Model. 2022 Feb 14;62(3):627-631. (PMID: 35072475) Clin Med (Lond). 2020 Jul;20(4):e109-e113. (PMID: 32571783) Sci Transl Med. 2021 Jun 30;13(600):. (PMID: 34103407) J Infect Dis. 2021 Sep 17;224(6):989-994. (PMID: 34260717) BMJ. 2020 Sep 1;370:m3320. (PMID: 32873575) JAMA Pediatr. 2021 Jun 1;175(6):594-600. (PMID: 33512440) Cell. 2020 Sep 3;182(5):1284-1294.e9. (PMID: 32730807) N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274) Nature. 2020 Dec;588(7839):682-687. (PMID: 33045718) MMWR Morb Mortal Wkly Rep. 2021 Feb 05;70(5):174-177. (PMID: 33539333) Lancet Reg Health Am. 2021 Oct;2:100027. (PMID: 34642685) Nat Immunol. 2021 Jan;22(1):67-73. (PMID: 33169014) JAMA Pediatr. 2021 Aug 1;175(8):817-826. (PMID: 33885740) Int J Environ Res Public Health. 2021 May 24;18(11):. (PMID: 34074005) Front Immunol. 2020 Sep 11;11:1920. (PMID: 33013843) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Nature. 2021 May;593(7857):130-135. (PMID: 33684923) Ultrasound Obstet Gynecol. 2021 Jun;57(6):974-978. (PMID: 33798280) |
| معلومات مُعتمدة: | INV-017035 United States GATES Bill & Melinda Gates Foundation; K08 AI141728 United States AI NIAID NIH HHS; K12 HD052163 United States HD NICHD NIH HHS; K23 AI127886 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Adaptive immunity; COVID-19; Immunoglobulins; Infectious disease |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20220517 Date Completed: 20220623 Latest Revision: 20231106 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9309042 |
| DOI: | 10.1172/jci.insight.157354 |
| PMID: | 35579965 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2379-3708 |
|---|---|
| DOI: | 10.1172/jci.insight.157354 |